<DOC>
	<DOCNO>NCT02831205</DOCNO>
	<brief_summary>The purpose study determine whether ABSORB bioresorbable vascular scaffold non-inferior XIENCE everolimus-eluting cobalt-chromium stent respect target-lesion failure ( TLF ) 1 year .</brief_summary>
	<brief_title>Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents Diffuse Long Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<criteria>Age 18 Diffuse long native coronary artery stenosis ( &gt; 50 % visual estimate ) lesion length 40 mm require least 2 overlapped stent referencevessel diameter 2.5 3.75 mm visual assessment Patients silent ischemia , stable unstable angina pectoris , acute myocardial infarction include NSTEMI STEMI The patient guardian agree study protocol schedule clinical followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethical Committee respective clinical site Subject know hypersensitivity contraindication device material ingredient ( everolimus , poly ( Llactide ) , poly ( DLlactide ) , lactide , lactic acid ) cobalt , chromium , nickel , platinum , tungsten , acrylic , fluoro polymer adequately premedicated Subject know allergic reaction , hypersensitivity , contraindication aspirin ; clopidogrel prasugrel ticagrelor ; heparin therefore adequately treat study medication An elective surgical procedure plan would necessitate interruption antiplatelet drug within 12 procedure STEMI require primary percutaneous coronary intervention Cardiogenic shock Restenotic lesion Left main Extreme angulation ( ≥90° ) excessive tortuosity ( ≥two 45° angle ) proximal within target lesion Heavy calcification proximal within target lesion Compromised leave ventricular dysfunction ( LVEF &lt; 30 % ) At time screening , subject malignancy remission Terminal illness life expectancy &lt; 1 year Patients actively participate another drug device investigational study , complete primary endpoint followup period Patient 's pregnant breastfeeding childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>bioresorbable vascular scaffold</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>